Abstract:There is an urgent need for the introduction of novel and better (i.e., improved risk-benefit profile) compounds for the treatment of major psychiatric disorders, in particular mood and psychotic disorders. However, despite increased societal awareness and a rising public and professional demand for such agents from patients and physicians, the pharmaceutical industry continues to close down its psychopharmacology research facilities in reaction to the lack of success with the search for new psychotropics. It is high time to stop this untoward trend and explore "new" lines of investigation to solve the current crisis in psychopharmacological research. In line with the prevailing molecular view in drug research in general, also in psychopharmacology mechanistic explanations for drug effects are "traditionally" looked for at the level of molecular targets, like receptors and transporters. Also, more recent approaches, although using so-called systems- and function-based approaches to model the multidimensional characteristics of psychiatric disorders and psychotropic drug action, still emphasize this search strategy for new therapeutic leads by identification of single molecules or molecular pathways. This "psychomolecular gaze" overlooks and disregards the fact that psychotropic agents usually are highly hydrophobic and amphipathic/amphiphilic agents that, in addition to their interaction with membrane-bound proteins in the form of e.g. receptors or transporters, also interact strongly with the lipid component of cellular membranes. Here we suggest to develop a program of systematic, whole-cell level based, investigation into the role of these physical-chemical cellular membrane interactions in the therapeutic action of known psychotherapeutics. This complementary yet conceptually different approach, in our opinion, will complement drug development in psychopharmacology and thereby assist in overcoming the current crisis. In this way the "old" physical theory of drug action, which antedates the current, primary molecular, paradigm may offer "new" options for lead discovery in psychopharmacological research.

Damage detection in metal structures using acoustic emission

Time to Re-Engage Psychiatric Drug Discovery by Strengthening Confidence in Preclinical Psychopharmacology

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?

Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders

Veterinary e-CPD: a new model for providing online continuing professional development for the veterinary profession.

Network-based drug repurposing for psychiatric disorders using single-cell genomics

Leveraging pleiotropy for the improved treatment of psychiatric disorders

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Cross‐species Studies of Cognition Relevant to Drug Discovery: a Translational Approach

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options

Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

Entering the era of computationally driven drug development

Animal models of major depressive disorder and the implications for drug discovery and development

Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Assessing the Alignment of Biomedical Research and Clinical Translation

Predicting treatment outcome in depression: an introduction into current concepts and challenges

Innovative solutions to novel drug development in mental health.

Implementation of functions in R tool in parallel environment